The study presents a potential alternative to adeno-associated virus (AAV)-mediated gene therapy, addressing the exclusion of patients with preexisting anti-AAV antibodies. Medical Xpress ...

In the early phase of its life cycle, the adenovirus provides the machinery needed to generate new AAV particles; in its late phase, it produces structural proteins and assembles new copies of itself.

More recently, the Vector Development Laboratory merged with our group, and we have expanded our services to offer AAV, first-generation adenovirus (FGAd), helper-dependent adenovirus (HDAd), ...